Skip to content

Author

Öztürk Ateş

We have 5 of 137 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Mucosal, Ocular, and Pulmonary Adverse Events Reported with Datopotamab Deruxtecan: An Indication-Restricted Disproportionality Analysis of the FDA Adverse Event Reporting System

Background/Objectives: Datopotamab deruxtecan was approved in 2025 for hormone receptor-positive, HER2-negative metastatic breast cancer and for EGFR-mutated non-small cell lung cancer (NSCLC); its safety profile in routine use has not been described. We characterized adverse event reporting for the agent and asked whe...

Osman Bilge Kaya, B. Karabuğa, E. Aydemir et al. · 0 citations
Open access Aug 2026

Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

Multidrug chemotherapy was associated with lower hazards of progression or death and of death than gemcitabine monotherapy in the primary overlap-weighted analysis and should be interpreted descriptively because of the small sample size, later treatment era, and potential residual confounding.

F. Kuş, F. Atalah, Gökhan Şahin et al. · 0 citations
Aug 2026

Crossing the milestone: landmark-based conditional survival after first-line CDK4/6 inhibitor therapy in HR+/HER2−metastatic breast cancer

Landmark-based conditional survival analysis provides clinically meaningful, time-updated prognostic information in HR+/HER2- mBC treated with first-line CDK4/6 inhibitors and support the integration of milestone-based conditional survival estimates alongside conventional baseline survival metrics in the CDK4/6i era.

T. Önder, Öztürk Ateş · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.